Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Yaoxue Xuebao ; 57(6):1808-1815, 2022.
Article in Chinese | EMBASE | ID: covidwho-1998089


To investigate the effect of Fufang yinhua jiedu (FFYH) granules against coronavirus and its potential mechanism, we used Huh7, Huh7.5, H460, and C3A cell lines as in vitro models to evaluate the cytotoxicity and antiviral activity of FFYH by observation of cell pathogenic effect (CPE);and then the inhibitory effect of FFYH on the transcription expression of coronavirus RNA and inflammatory factor mRNA were evaluated by quantitive reverse transcription PCR (qRT-PCR);finally, the inhibitory effect of FFYH on the expression of coronavirus protein and its underlying mechanism against coronavirus were investigated by Western blot and immunofluorescence. Our results indicated that 50% toxic concentration (TC50) FFYH on Huh7, Huh7.5, H460, and C3A cells were 2 035.21, 5 245.69, 2 935.28 and 520 µg·mL-1, respectively;50% inhibitory concentration (IC50) of FFYH on HCoV-229E in Huh7 and Huh7.5 cells were 438.16 and 238.54 µg·mL-1 with safety index (SI) of 4.64 and 21.99, respectively;IC50 of FFYH on HCoV-OC43 in H460 cells was 165.13 µg·mL-1 with SI of 17.78. Moreover, FFYH not only could inhibit the replication of coronaviruses (HCoV-OC43 and HCoV-229E) through inhibiting the transcription of viral RNA and the expression of viral protein, but also effectively suppress the expression of inflammatory factors interleukin-6 (IL-6), tumor necrosis factor α (TNF-α) and interleukin-8 (IL-8) at mRNA level caused by coronaviruses, which might be associated with the inhibitory effect of FFYH on mitogen-activated protein kinase (MAPK) pathway and the nuclear translocation of nuclear transcription factor-κB (NF-κB). In summary, our results demonstrated that FFYH exhibited a good in vitro anti-coronavirus effect, which provides a theoretical basis for its clinical use in the treatment of anti-coronavirus pneumonia.

International Journal of Chinese & Comparative Philosophy of Medicine ; 18(2):75-80, 2020.
Article in Chinese | Web of Science | ID: covidwho-1023146


As a tentative reply to Prof. Hans-Martin Sass's article entitled "The Coronavirus also Attacks Political and Corporate Bodies," this article elaborates on mainland China's national collective fight against COVID-19 with respect to Confucian familism. I apply the ethical principles of Confucian familism at the family, country, and international levels to morally evaluate the whole nation's fight against the pandemic. My discussion supports Prof. Sass's arguments that "life is interconnected" and that "modern societies are symbiotic, complex, and adoptable living beings of natural persons."

Zhonghua Zhong Liu Za Zhi ; 42(3): 187-191, 2020 Mar 23.
Article in Chinese | MEDLINE | ID: covidwho-590726


Objective: From December 2019, the new coronavirus pneumonia (COVID-19) broke out in Wuhan, Hubei, and spread rapidly to the nationwide. On January 20, 2020, the National Health Committee classified COVID-19 pneumonia as one of B class infectious diseases and treated it as class A infectious disease. During the epidemic period, the routine diagnosis and treatment of tumor patients was affected with varying degrees. In this special period, we performed the superiority of the multi-disciplinary team of diagnosis and treatment, achieved accurate diagnosis and treatment of patients with hepatobiliary malignant tumors, provided support for these patients with limited medical resources, and helped them to survive during the epidemic period.On the basis of fully understanding the new coronavirus pneumonia, the treatment strategy should be changed timely during the epidemic, and more appropriate treatment methods should be adopted to minimize the adverse effect of the epidemic on tumor treatment.

Coronavirus Infections/prevention & control , Coronavirus , Cross Infection/prevention & control , Liver Neoplasms/surgery , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Betacoronavirus , Biliary Tract Neoplasms/diagnosis , COVID-19 , China , Communicable Disease Control/methods , Coronavirus/pathogenicity , Coronavirus Infections/epidemiology , Disease Outbreaks , Humans , Immunocompromised Host , Liver Neoplasms/diagnosis , Patient Care Planning , Pneumonia, Viral/epidemiology , Risk , SARS-CoV-2